Results 141 to 150 of about 53,162 (283)

Adaptive Evolution and Distinct Mutation Signatures of Full‐Length HBV Quasispecies in HBeAg‐Negative Chronic Hepatitis B

MicrobiologyOpen, Volume 14, Issue 6, December 2025.
HBeAg‐negative chronic hepatitis B harbors a highly heterogeneous HBV quasispecies shaped by region‐specific selection. Adaptive strategies underpinning viral persistence include: BCP/PreC mutations supporting replication, PreS/S mutations enabling immune evasion, and overlapping Pol/S mutations maintaining viral fitness.
Changhui Wu, Fengwei Liu, Xiao Li, Xiaojin Li, Hui Li, Sihang Zhang, Xiaohui Yan, Taicheng Zhou, Jia Wei   +8 more
wiley   +1 more source

A case report: Complications of trans arterial embolization in managing ruptured hemorrhage of hepatocellular carcinoma

Malignancy Spectrum, Volume 2, Issue 4, Page 204-208, December 2025.
TAE is an effective treatment for liver cancer rupture and bleeding. When treating patients with liver cancer rupture and bleeding, precise embolization is required during the TAE procedure to avoid extensive embolization. After liver cancer rupture and bleeding, a large amount of intra‐abdominal hemorrhage may induce complications such as hepatic ...
Gang Tong, Yang Hua, Renhua Huang, Junwen Hu   +3 more
wiley   +1 more source

Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study. [PDF]

J Virus Erad
Wang YH, Tao YC, Wang ML, Song CR, Peng JN, Chen EQ.   +5 more
europepmc   +1 more source

Hepatitis B Virus Genotype D Predominates HBsAg-Positive Egyptian Blood Donors and Is Mainly Associated with a Negative HBeAg Serostatus [PDF]

, 2013
Febee E. Habil, Wafaa K.M. Mahdi, Sayed F. Abdelwahab, Mohamed Abdel-Hamid   +3 more
openalex   +1 more source

A Step‐by‐Step Workflow for Performing In Silico Clinical Trials With Nonlinear Mixed Effects Models

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 1949-1964, December 2025.
ABSTRACT In silico clinical trials (ISCT) are computational frameworks that employ mathematical models to generate virtual patients and simulate their responses to new treatments, treatment regimens, or medical devices via simulations mirroring real‐world clinical trials.
Javiera Cortés‐Ríos, Mindy Magee, Anna Sher, William J. Jusko, Rajat Desikan   +4 more
wiley   +1 more source

Dual defects in HBsAg antigenicity and secretion caused by the C138R mutation in the S gene trigger occult hepatitis B virus infection. [PDF]

J Transl Med
Hong X, Chen X, Zhang P, Gao Z, Tao C, Wang H, Zhang Z.   +6 more
europepmc   +1 more source

Hepatitis B surface antigenemia (HBsAg) among pregnant women in southern Nigeria

, 2014
BT Utoo
openalex   +2 more sources

Comparison between Lumipulse Presto HBsAg-HQ and iTACT-HBsAgin Chronic Hepatitis B with Seroclearance of HBsAg by Architect HBsAg QT

, 2021
Mariko Kobayashi, Fumitaka Suzuki, Tetsuya Hosaka, Norio Akuta, Hitomi Sezaki, Satoshi Saitoh, Yusuke Kawamura, Shunichiro Fujiyama, Masahiro Kobayashi, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada   +12 more
openalex   +2 more sources

Long‐Term Outcomes of Patients Who Receive a Liver Transplant for Hepatitis B With Limited Use of Hepatitis B Immunoglobulin

Clinical Transplantation, Volume 39, Issue 12, December 2025.
ABSTRACT Chronic hepatitis B virus (HBV) infection is a leading cause of cirrhosis and hepatocellular carcinoma (HCC). Post‐transplant HBV reinfection represents an important post‐liver transplantation (LT) complication, which can result in death or graft loss.
Giovanni A. Roldan, Erica Loon, John Lake, Nicholas Lim   +3 more
wiley   +1 more source

Interferon therapy-induced reduction in PD-1 + CD8 + and CD160 + CD8 + T cells is associated with functional cure in hepatitis B. [PDF]

BMC Infect Dis
Zhou D, Liu J, Jia J, Li H, Qin L, Zhang Z, Cao Z.   +6 more
europepmc   +1 more source